Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of May 2020, specifically dated May 11, 2020. The report details a corporate governance action regarding executive compensation following the Annual General Meeting and shareholder approval of the 2020 Remuneration Policy.
Key Financial Metrics
The filing does not report consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for the company. It focuses exclusively on a specific executive compensation transaction.
- Transaction Type: Conditional share award ("top-up") under the 2017 Performance Share Plan.
- Recipient: Ms. E. Walmsley, Chief Executive Officer.
- Award Volume: 17,830 Ordinary Shares.
- Valuation Price: £16.814 per share (fixed price used for the February 2020 award, higher than the May 5, 2020 closing price of £16.68).
- Total Award Level: The top-up increases the CEO's total 2020 award to 575% of base salary (up from 550%).
Material Changes
The primary material change is the adjustment to the CEO's long-term incentive plan to align with the newly approved 2020 Remuneration Policy. The Remuneration Committee elected to use a higher share price (£16.814) rather than the lower market price on the day preceding the award to prevent the CEO from benefiting from a temporary share price dip.
Guidance, Outlook, and Performance Measures
The filing confirms the performance measures for the 2020 awards, covering the three-year period from January 1, 2020, to December 31, 2022. Vesting is contingent on the following metrics:
- Relative Total Shareholder Return (TSR) (30%): Compared against a peer group of nine other global pharmaceutical companies. Vesting ranges from 0% (6th or below) to 100% (1st-3rd).
- Adjusted Free Cash Flow (AFCF) (30%): Targets range from a threshold of £9.99bn (25% vesting) to a maximum of £11.84bn (100% vesting).
- Innovation Sales (20%): Specific product targets are not disclosed due to commercial sensitivity. Vesting ranges from 25% at threshold to 100% at 122% of the threshold.
- Pipeline Progress (20%): A new measure split equally between Pivotal Trial Starts and Major Regulatory Approval milestones. Vesting is based on points allocated by forecast commercial value.
Holding Period: Shares are subject to an additional two-year holding period post-vesting (five years total), during which they carry dividend rights but may be forfeited only if the CEO is terminated for cause.
Investor Verification Checklist
- Verify the final vesting percentage of the CEO's award against the disclosed AFCF and TSR targets at the end of the 2022 performance period.
- Monitor the disclosure of the specific "Innovation Sales" targets, which are currently withheld for commercial sensitivity.
- Confirm the number of Pivotal Trial Starts and Regulatory Approvals achieved to assess the Pipeline Progress component.
- Review future filings for any changes to the peer group used for the Relative TSR calculation.